Patient P-01820
Therapy response
Stable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
11%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S17
- Day 12 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 12.
Primary contributors, last 14 days
- Nutritional resilience+10
- GI instability-9
- Treatment adherence+6
- Inflammatory activity-4
- Toxicity+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion18.2/100
improving · -11.0 vs previous 14 d
Toxicity
Blood13.9/100
worsening · +2.6 vs previous 14 d
Sleep quality
Wearable45.9/100
improving · +3.2 vs previous 14 d
Energy level
Daily log6.5/10
improving · +0.7 vs previous 14 d
Stress level
Daily log3.7/10
improving · -0.5 vs previous 14 d
Steps
Wearable3,819
improving · +306 vs previous 14 d
Adherence
Companion95.3 %
stable · -0.7 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 70 from the failing basin, 26 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Alcoholperturbation · steering -8.4
- Rapid metabolizerhidden · steering -8
- Enterobacteriaceae elevatedhidden · steering -7.4
- IL6 high-expression varianthidden · steering -7.3
- Alcoholdetractor · GI +4.8 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Alcohol+4.8detractor · 95%
- Simple carbohydrates+1.1no signal · 22%
- Insoluble fibre-0.7no signal · 17%
- Histamine load+0.5no signal · 15%
- Spicy / capsaicin+0.3no signal · 15%
- Dietary fat load-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
- Butyrate / short-chain fatty acid production ↓25
- MicrobiomeF. prausnitzii depleted
- Autonomic recovery ↑20
- Wearable3,819 steps/day
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 48/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 7.0 h
- Steps
- 3,432
- Resting HR
- 73 bpm
Daily log: GI score 18, nutritional resilience 67, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01609 | 49% | S12 | GI-04 | no change | 48 |
| P-01562 | 48% | S04 | HY-01 | no change | 49 |
| P-01455 | 47% | S01 | GI-04 | improved | 61 |
| P-01522 | 47% | S06 | DT-01 | no change | 62 |
| P-01374 | 46% | S08 | HY-01 | improved | 49 |
| P-01487 | 46% | S03 | — | — | 48 |
| P-01861 | 46% | S12 | HY-01 | improved | 47 |
| P-01555 | 45% | S06 | GI-04 | improved | 56 |
| P-01633 | 45% | S16 | GI-04 | no change | 55 |
| P-01392 | 44% | S03 | — | — | 47 |
| P-01596 | 44% | S08 | — | — | 51 |
| P-01644 | 44% | S03 | — | — | 50 |